Catalyst Financial Partners LLC increased its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 10.0% in the fourth quarter, HoldingsChannel.com reports. The fund owned 24,069 shares of the company’s stock after buying an additional 2,182 shares during the period. Johnson & Johnson comprises approximately 0.6% of Catalyst Financial Partners LLC’s investment portfolio, making the stock its 27th biggest holding. Catalyst Financial Partners LLC’s holdings in Johnson & Johnson were worth $4,981,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Abich Financial Wealth Management LLC purchased a new position in Johnson & Johnson in the 3rd quarter worth $26,000. Cresta Advisors Ltd. purchased a new position in Johnson & Johnson in the 4th quarter worth $26,000. DecisionPoint Financial LLC raised its stake in Johnson & Johnson by 104.2% in the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock worth $30,000 after acquiring an additional 75 shares during the last quarter. Family CFO Inc purchased a new position in Johnson & Johnson in the 4th quarter worth $31,000. Finally, Bay Harbor Wealth Management LLC raised its stake in Johnson & Johnson by 49.0% in the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock worth $31,000 after acquiring an additional 49 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.
Key Stories Impacting Johnson & Johnson
Here are the key news stories impacting Johnson & Johnson this week:
- Positive Sentiment: Leerink Partners upgraded Johnson & Johnson from “Market Perform” to “Outperform” and lifted its price target to $265 from $252, citing accelerating growth prospects from new drug launches and stronger oncology and immunology franchises. Johnson & Johnson upgraded at Leerink on growth prospects
- Positive Sentiment: Analysts highlighted J&J’s pipeline momentum, including Tremfya and newly approved Icotyde as key drivers for immunology growth as Stelara faces biosimilar pressure, reinforcing the company’s post-Stelara strategy. Tremfya, Icotyde Lead J&J’s Post-Stelara Immunology Strategy
- Positive Sentiment: J&J also announced the global launch of the Shockwave C2 Aero Coronary IVL Catheter, adding another product launch that supports its cardiovascular growth story. Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter
- Neutral Sentiment: J&J remains in focus as a defensive, high-quality name with one of the market’s strongest credit ratings, which may keep income-focused investors interested but is less likely to be a near-term catalyst. The 2 US Companies With a Better Credit Rating Than Uncle Sam Belong in Every Retirement Portfolio
- Neutral Sentiment: The company also got attention in articles emphasizing its safety, dividend appeal, and retirement-portfolio status, which supports the stock’s defensive reputation rather than signaling a major fundamental change. Russell 1000 Dividend ETF Hits 125 as Johnson & Johnson Leads The Safety Test
Analyst Upgrades and Downgrades
Get Our Latest Report on Johnson & Johnson
Insider Transactions at Johnson & Johnson
In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the transaction, the executive vice president owned 23,003 shares in the company, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Timothy Schmid sold 22,623 shares of the company’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the completion of the transaction, the executive vice president owned 26,769 shares of the company’s stock, valued at approximately $6,540,469.77. This trade represents a 45.80% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 30,142 shares of company stock valued at $7,360,528. Insiders own 0.16% of the company’s stock.
Johnson & Johnson Trading Up 2.8%
NYSE JNJ opened at $230.43 on Thursday. The company has a market capitalization of $554.69 billion, a PE ratio of 26.64, a P/E/G ratio of 2.20 and a beta of 0.27. The company has a fifty day moving average of $235.82 and a 200 day moving average of $221.47. Johnson & Johnson has a 1 year low of $146.12 and a 1 year high of $251.71. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.02. The company had revenue of $24.06 billion during the quarter, compared to the consensus estimate of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The firm’s quarterly revenue was up 9.9% on a year-over-year basis. During the same period in the previous year, the firm posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Research analysts forecast that Johnson & Johnson will post 11.57 earnings per share for the current year.
Johnson & Johnson Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be given a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.3%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date is Tuesday, May 26th. Johnson & Johnson’s payout ratio is currently 60.12%.
Johnson & Johnson Profile
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
